Inflammatory linear verrucous epidermal nevus (ILVEN) is a benign cutaneous hamartoma characterized by intensely erythematous, pruritic, and inflammatory papules that occur as linear bands along the lines of Blaschko. There is a considerable clinical and histological resemblance between ILVEN and linear psoriasis, lichen striatus, linear lichen planus, and invasion of epidermal nevus by psoriasis. The pathogenesis of ILVEN is unknown. It is regarded as a genetic dyskeratotic disease reflecting genetic mosaicism. Here, a case of vulvar and perianal condyloma superimposed ILVEN is presented. 1. Introduction Inflammatory linear verrucous epidermal nevus (ILVEN) is a relatively uncommon benign cutaneous hamartoma described by Altman and Mehregan in 1971 [1]. It is characterized by intensely pruritic, erythematous, inflammatory papules coalescing into well-demarcated verrucous plaques in a linear distribution. Patients seek help for its symptoms and cosmetic appearance [2]. Medical management is extremely variable but unfortunately does not result in complete recovery. On the other hand, surgical excision of lesions is not preferable due to extensive scarring and relapse of disease [3]. Here,a case of vulvar and perianal condyloma superimposed ILVEN is presented. 2. Case Presentation A 21-year-old virgo patient, has presented with a huge amount of vulvar and perianal condylomas. Surgical excision was planned. But in physical examination of patient, erythematous scaly plaques were seen unilaterally on the right side of body. Detailed medical history revealed that, erythematous lesions, of linear or grouped distribution, involving only right side of body; upper trunk, axilla, and lower extremity unilaterally had existed since a few years after birth. Lesions were extremely pruriginous and aggravated with heat. There were no pathological antecedents or previous family history of the disease. Dermatological examination revealed papular lesions and erythematous plaques with areas of scaling and crusts, linearly distributed at the right side of the body. (Figures 1(a), 1(b), and 1(c)). Disease was diagnosed as ILVEN by histopathological examination. Besides, laboratory tests including C3, C4, immunoglobulin (Ig)A, IGM, IGE, IGG anti-HAV IGM, and anti-HAV IGG were performed. Laboratory investigations showed mild anemia (hemoglobin 10.5？g/dL), an elevated erythrocyte sedimentation rate (45？mm/h), and an elevated C-reactive protein level (36.3？mg/L, normal < 8.0？mg/L). Liver enzymes, renal function test results, and immunoglobulin levels were normal. Results of tests
References
[1]
J. Altman and A. H. Mehregan, “Inflammatory linear verrucose epidermal nevus,” Archives of Dermatology, vol. 104, no. 4, pp. 385–389, 1971.
[2]
B. J. Lee, A. J. Mancini, J. Renucci, A. S. Paller, and B. S. Bauer, “Full-thickness surgical excision for the treatment of inflammatory linear verrucous epidermal nevus,” Annals of Plastic Surgery, vol. 47, no. 3, pp. 285–292, 2001.
[3]
G. Micali, M. R. Nasca, and M. L. Musumeci, “Effect of topical calcipotriol on inflammatory linear verrucous epidermal nevus,” Pediatric Dermatology, vol. 12, no. 4, pp. 386–387, 1995.
[4]
H. Hamm and R. Happle, “Inflammatory linear verrucous epidermal nevus (ILVEN) in a mother and her daughter,” The American Journal of Medical Genetics, vol. 24, no. 4, pp. 685–690, 1986.
[5]
K. Goldman and P. C. Don, “Adult onset of inflammatory linear verrucous epidermal nevus in a mother and her daughter,” Dermatology, vol. 189, no. 2, pp. 170–172, 1994.
[6]
Q. A. Alsaleh, A. Nanda, H. M. M. Hassab-el-Naby, and M. F. Sakr, “Famialial inflammatory linear verrucous epidermal nevus (ILVEN),” International Journal of Dermatology, vol. 33, no. 1, pp. 52–54, 1994.
[7]
C. Morag and A. Metzker, “Inflammatory linear verrucous epidermal nevus: report of seven new cases and review of literature,” Pediatric Dermatology, vol. 3, no. 1, pp. 15–18, 1985.
[8]
M. J. Cheesbrough and P. E. Kilby, “The inflammatory linear verrucous epidermal naevus: a case report,” Clinical and Experimental Dermatology, vol. 3, no. 3, pp. 293–298, 1978.
[9]
B. J. Fox and N. A. Lapins, “Comparison of treatment modalities for epidermal nevus: a case report and review,” Journal of Dermatologic Surgery and Oncology, vol. 9, no. 11, pp. 879–885, 1983.
[10]
A. D. Antuono, R. Balestri, S. Zauli et al., “Carbon dioxide laser: first line therapy in vulvar inflamatuar linear verrucous epidermal nevus,” Dermatology and Therapy, vol. 25, pp. 92–94, 2012.
[11]
L. Resta, M. Troia, S. Russo et al., “Variations of lymphocyte sub-populations in vulvar condylomata during therapy with β-interferon,” European Journal of Gynaecological Oncology, vol. 13, no. 5, pp. 440–444, 1992.
[12]
M. Scott, M. Nakagawa, and A.-B. Moscicki, “Cell-mediated immune response to human papillomavirus infection,” Clinical and Diagnostic Laboratory Immunology, vol. 8, no. 2, pp. 209–220, 2001.
[13]
M. Scheffner, B. A. Werness, J. M. Huibregtse, A. J. Levine, and P. M. Howley, “The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53,” Cell, vol. 63, no. 6, pp. 1129–1136, 1990.
[14]
D. K. Gill, J. M. Bible, C. Biswas et al., “Proliferative T-cell responses to human papillomavirus type 16 E5 are decreased amongst women with high-grade neoplasia,” Journal of General Virology, vol. 79, no. 8, pp. 1971–1976, 1998.
[15]
H. J. Bontkes, T. D. de Gruijl, A. Bijl et al., “Human papillomavirus type 16 E2-specific T-helper lymphocyte responses in patients with cervical intraepithelial neoplasia,” Journal of General Virology, vol. 80, no. 9, pp. 2453–2459, 1999.
[16]
A. E. Luque, L. M. Demeter, and R. C. Reichman, “Association of human papillomavirus infection and disease with magnitude of human immunodeficiency virus type 1 (HIV-1) RNA plasma level among women with HIV-1 infection,” Journal of Infectious Diseases, vol. 179, no. 6, pp. 1405–1409, 1999.
[17]
M. ？zdemir, A. Balevi, and H. Esen, “An inflammatory verrucous epidermal nevus concomitant with psoriasis: treatment with adalimumab,” Dermatology Online, vol. 18, no. 10, p. 11, 2012.
[18]
A. Zvulunov, M. H. Grunwald, S. Halvy, et al., “Topical calcipotriol for treatment of inflammatory linear verrucous epidermal nevus,” Archives of Dermatology, vol. 133, no. 5, pp. 567–568, 1997.
[19]
M. L. Welch, K. J. Smith, H. G. Skleton et al., “In addition cell proliferation may be clonally dysregulated. Military medial consortium for the advancement of retroviral research,” Journal of the American Academy of Dermatology, vol. 29, pp. 242–248, 1993.
[20]
M. Welch, K. J. Smith, H. G. Skelton, et al., “Inflammatory linear verrucous epidermal nevus in patients with positive results of tests for human immunodeficiency virus 1,” Cutis, vol. 55, no. 6, pp. 365–368, 1995.
[21]
O. Dereure, C. Paillet, F. Bonnel, and J.-J. Guilhou, “Inflammatory linear verrucous epidermal naevus with auto-immune thyroiditis: coexistence of two auto-immune epithelial inflammations?” Acta Dermato-Venereologica, vol. 74, no. 3, pp. 208–209, 1994.
[22]
L. Zhuang and Z. Wenyuan, “Inflammatory linear verrucose epidermal nevus coexisting with lichen amyloidosus,” Journal of Dermatology, vol. 23, no. 6, pp. 415–418, 1996.
[23]
L. E. Golitz and W. L. Weston, “Inflammatory linear verrucous epidermal nevus. Association with epidermal nevus syndrome,” Archives of Dermatology, vol. 115, no. 10, pp. 1208–1209, 1979.
[24]
R. Happle, “Child naevus is not ILVEN,” Journal of Medical Genetics, vol. 28, no. 3, p. 214, 1991.
[25]
S. Al-Enezi, A. M. Huber, B. R. Krafchik, and R. M. Laxer, “Inflammatory linear verrucous epidermal nevus and arthritis: a new association,” The Journal of Pediatrics, vol. 138, no. 4, pp. 602–604, 2001.
